Real-World study tracks how IBD patients choose between IV and injectable vedolizumab

NCT ID NCT04989907

Completed Knowledge-focused Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study observed 92 adults with Crohn's disease or ulcerative colitis who were receiving vedolizumab either as an intravenous infusion or a subcutaneous injection. Researchers tracked treatment patterns, such as whether patients stayed on their current form or switched, over 12 months. The goal was to understand real-world choices and outcomes without influencing how patients were treated.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: vedolizumab
What this could lead to: If successful, this study could help doctors and patients make more informed decisions about which form of vedolizumab (IV or injection) works best in daily life.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient or doctor preferences rather than the treatment itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLITIS, ULCERATIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease inflammatory bowel disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLITIS, ULCERATIVE CROHNS DISEASE INFLAMMATORY BOWEL DISEASES

Contacts and locations

Locations

Bauchzentrum INSELSPITAL, Universitatsspital Bern

Bern, 3010, Switzerland
Clarunis AG

Basel, 4002, Switzerland
Gastroenterologische Praxis Balsiger, Seibold & Partner Crohn-Colitis-Zentrum

Bern, 3012, Switzerland
Kantonsspital St. Gallen

Sankt Gallen, Canton of St. Gallen, 9007, Switzerland
Universitatsspital Zurich

Zurich, 8091, Switzerland
Zentrum fur Gastroenterologie und Hepatologie AG

Zurich, 8048, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.